Daiichi Sankyo Company and Ranbaxy Laboratories announced today that the latter's New Drug Discovery Research has been transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global research and development (R&D) structure of the Daiichi Sankyo Group.
Established in 1994, the New Drug Discovery Research has high-level synthetic chemical research capabilities. According to the stock exchange announcement, the transaction has been approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology.
The new organisation, Daiichi Sankyo Life Science Research Center in India, based in Gurgaon, will play a key role in the Group's global Drug Discovery research to create promising new drugs especially in the area of low molecular weight infections and inflammatory disease treatments.